Overview

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®

...
More »
Stock Quote
NASDAQ - CDXC
Price$3.79
Change (%) Stock is Down 0.14 (3.56%)
Volume432,148
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
09/21/18TRU NIAGEN® PRO to be Featured at the Academy of Integrative Health & Medicine Annual Conference
Healthcare practitioners will have first look at new high-dose TRU NIAGEN PRO product IRVINE, Calif., Sept. 21, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced it will exhibit at the AIHM Annual Conference 2018 in San Diego, CA. The sole active ingredient in Tru Niagen is nicotinamide riboside, a unique fo... 
Printer Friendly Version
09/20/18New TRU NIAGEN PRO Launched for Expansive Distribution by Healthcare Practitioners
Addressing aging population, TRU NIAGEN PRO now available for distribution by healthcare practitioners for patient health and wellness IRVINE, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced the launch of TRU NIAGEN PRO (60ct, 300mg per capsule), a partnership with Natural Partners Fullscrip... 
Printer Friendly Version
09/18/18ChromaDex and Dartmouth College File Patent Infringement Lawsuit Against Elysium Health
IRVINE, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today that ChromaDex, Inc. and Trustees of Dartmouth College filed a patent infringement complaint in the United States District Court for the District of Delaware against Elysium Health, Inc. (“Elysium”). The complaint alleges that Elysium’s ... 
Printer Friendly Version
What's New
DateTitle
09/05/18
September 2018 Investor Presentation PDF
08/09/18
Q2 2018 Earnings Presentation PDF
07/17/18
July 2018 Investor Presentation PDF
08/09/18
2018 Q2 Quarterly Report on Form 10Q PDF
04/27/18
2018 Proxy Statement  PDF
03/15/18
2017 Annual Report on Form 10-K PDF
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.